Psoriasis
📧 Sign up to get email alerts when something new happens for Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-03-17Clinical Trial Update: Koebner's Phenomenon in Psoriasis and Lichen Planus [NA]
A ClinicalTrials.gov entry shows withdrawal of a trial investigating Koebner phenomenon in psoriasis and lichen planus.
-
FDA label_change · 2026-03-16FDA Approved: DESOXIMETASONE — Supplemental Application (Saptalis Pharmaceuticals, LLC.)
FDA approved a supplemental application for desoximetasone (Saptalis Pharmaceuticals, LLC.), resulting in updated labeling for this topical …
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis [NA]
A clinical trial update indicates Sirt3 LLC is sponsoring a study to evaluate Magnolia officinalis dietary supplement on immune biomarkers i…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
A Costa Rican registry study evaluating IL-23 inhibitors for psoriasis and psoriatic arthritis; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease [Phase 1]
Phase 1 study of S-4321 in autoimmune and immune-mediated diseases; the trial status is not yet recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-04EMA Authorised: Otezla (apremilast) — Amgen Europe B.V.
The European Medicines Agency authorised Otezla (apremilast) for Behçet syndrome, in addition to its established uses in psoriatic arthritis…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Proactive TDM Versus Standard Use of Biologics in Psoriasis [Phase 4]
A Phase 4 clinical trial comparing proactive therapeutic drug monitoring (TDM) versus standard biologic use in psoriasis is currently recrui…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis [NA]
A clinical trial is evaluating a topical nanoformulation of apremilast for localized plaque psoriasis. The study status is NOT_YET_RECRUITIN…
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant [Phase 4]
Phase 4 trial comparing methotrexate alone versus methotrexate plus an antidepressant for patients with psoriasis and comorbid depression or…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Methotrexate Versus Apremilast for Pruritus in Psoriasis [Phase 4]
Phase 4 clinical trial comparing methotrexate to apremilast for pruritus in psoriasis is listed as not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in Traditional Chinese Medicine
A clinical trial is planned to develop an ocular imaging-based predictive model of inflammatory skin diseases rooted in Traditional Chinese …
-
EMA approval · 2026-02-24EMA Authorised: Fymskina (ustekinumab) — Formycon AG
The EMA authorised Fymskina, an ustekinumab biosimilar from Formycon AG, for Crohn's disease, psoriasis, and psoriatic arthritis.
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Real-Life Evaluation of Guselkumab Dosing Interval Adjustments
A real-life study evaluating adjustments to guselkumab dosing intervals for psoriasis.
-
CLINICAL_TRIALS withdrawal · 2026-02-23Clinical Trial Update: Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy
A clinical trial evaluating guselekumab for shared pathways in psoriasis, psoriatic arthritis, and nonalcoholic fatty liver disease has been…
-
EMA approval · 2026-02-19EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
The EMA authorised Hulio, a biosimilar of adalimumab, for multiple inflammatory indications including hidradenitis suppurativa, psoriasis, u…
-
EMA approval · 2026-02-18EMA Authorised: Wezenla (ustekinumab) — Amgen Technology (Ireland) UC
EU authorization for Wezenla, a ustekinumab product from Amgen Technology (Ireland) UC, indicated for psoriasis, psoriatic arthritis, and Cr…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet [NA]
The study uses total-body PET imaging to quantify systemic and cutaneous inflammation in psoriasis patients before and after a nutritionally…
-
EMA approval · 2026-02-17EMA Authorised: Inflectra (infliximab) — Pfizer Europe MA EEIG
EMA authorised Inflectra (infliximab) as a biosimilar to Remicade for multiple inflammatory diseases including rheumatoid and psoriatic arth…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Role of Insulin Action in Psoriasis Pathogenesis
Columbia University sponsored a clinical trial investigating the role of insulin action in psoriasis pathogenesis has been terminated. The s…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Psoriatic Arthritis and Psoriasis Treatment Decision Aid [NA]
University of Pennsylvania-sponsored clinical trial evaluating a treatment decision aid for psoriatic arthritis and psoriasis has completed.
-
EMA approval · 2026-02-16EMA Authorised: Yesintek (ustekinumab) — Biosimilar Collaborations Ireland Limited
The European Medicines Agency authorised Yesintek, a biosimilar of ustekinumab, for use in psoriasis, psoriatic arthritis, and Crohn's disea…
-
EMA approval · 2026-02-16EMA Authorised: Hefiya (adalimumab) — Sandoz GmbH
EMA authorised Hefiya, a biosimilar adalimumab from Sandoz GmbH, for multiple inflammatory conditions including ankylosing spondylitis, hidr…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: SEquential Treatment of PSoriasis With Biologics
This clinical trial from Royal United Hospitals Bath NHS Foundation Trust is evaluating sequential biologic therapy for psoriasis and is cur…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis [Phase 4]
Phase 4 clinical trial update evaluating the effects of semaglutide on clinical outcomes and metabolic inflammation in patients with psorias…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: The CorEvitas Psoriasis (PSO) Registry
The CorEvitas Psoriasis Registry is currently enrolling participants by invitation to collect observational data on psoriasis.